

Qurient
Therapeutics

Q203 Update

Q203: MOA

- Bacteria killing by

  Inhibition of respiratory chain (cytochrome bc1 complex)



- Host anti-inflammation by

  Inhibition of 5 lipoxygenase

Nature Medicine 2013
Nature Communications 2016

Q203: Bacteria Killing Activity

- Mouse 4 weeks treatment model shows good efficacy
- Maximum efficacious dose at 10 mg/kg



(Nature Medicine 2013)

Q203: Anti-Inflammation

- Oral administration of Q203 inhibits production of LTB4



- Reduction in numbers of granuloma in mouse TB model



Untreated (vehicle) INH (15 mg/kg) Q203 (10 mg/kg)

(Nature Medicine 2013)

Q203: Preclinical Studies

- Absorption

  Mouse single dose in fasted condition shows long half life (~90 hour)

  Steady-state after 14 days of dosing

- Distribution

  Mouse mass balance study shows compound distribution to lung

- Metabolism

  Negative DDI sign from in vitro study

  No major metabolite

- Excretion

  Mainly excreted through feces

- Toxicity

  Well established NOAEL up to 28 days

Q203: Preclinical Studies

- Absorption

  Mouse single dose in fasted condition shows long half life (~90 hour)

  Steady-state after 14 days of dosing

- Distribution

  Mouse mass balance study shows compound distribution to lung

- Metabolism

  Negative DDI sign from in vitro study

  No major metabolite

- Excretion

  Mainly excreted through feces

- Toxicity

  Well established NOAEL up to 28 days

Q203: Phase 1 SAD

- Dose proportional increase of C_{max} and AUC_{last}
- No clinically significant changes in safety parameters including ECG
- Food increases absorption around 5 fold





Q203: Phase 1 MAD (on-going)

- Designed to support 14-day EBA study
- Dose escalation up to maximum anticipated efficacious level

Q203: Future Plan

- EBA study planned starting end of 2017

  Standard 14-day EBA with extended combination dosing phase with HRZ or innovative backbone (bedaquiline ?)



- Developing safety and efficacy profile in combination regimen from early stage

Acknowledgement